Search

Author/Creator Kanwar, Bittoo

1. All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐naïve patients with genotype 1 HCV infection. Issue 1 (28th May 2014)

Authors:
Wyles, David L.; Rodriguez‐Torres, Maribel; Lawitz, Eric; Shiffman, Mitchell L.; Pol, Stanislas; Herring, Robert W.; Massetto, Benedetta; Kanwar, Bittoo; Trenkle, James D.; Pang, Phil S.; Zhu, Yanni; Mo, Hongmei; Brainard, Diana M.; Subramanian, G. Mani; McHutchison, John G.; Habersetzer, Françoi...
Journal:
Hepatology
Issue:
Volume 60:Issue 1(2014:Jul.)
Page Start:
56
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Combination Therapy of Selective MMP9 Inhibitor and JAK Inhibitor Is Effective to Induce Disease Control in Mouse DSS Model of Colitis: 593. (October 2016)

Authors:
Kim, Sunhwa; Carr, Brian; Tong, Leah; Sobczyk, Monika; Zheng, Jim; Lu, Bing; Mikaelian, Igor; Brockett, Robert; Jin, Debi; Wang, Ruth; Kanwar, Bittoo; Smith, Victoria
Journal:
American journal of gastroenterology
Issue:
Volume 111(2016)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Genome-Wide Association Study to Characterize Serum Bilirubin Elevations in Patients with HCV Treated with Gs-9256, An HCV Ns3 Serine Protease Inhibitor. Issue 7 (October 2014)

Authors:
Nelson, David; Yoshida, Eric M; Paulson, Matthew S; Hengen, Paul N; Ge, Dongliang; Kanwar, Bittoo; McNally, John; Pang, Phillip S; Subramanian, G Mani; McHutchison, John G; Urbanek, Petr; Lawitz, Eric; Urban, Thomas J
Journal:
Antiviral therapy
Issue:
Volume 19:Issue 7(2014)
Page Start:
679
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P-269 A Combination Therapy of Selective MMP9 Inhibitor and JAK Inhibitors Is Efficacious in Mouse DSS Model of Colitis. (February 2017)

Authors:
Kim, Sunhwa; Carr, Brian; Tong, Leah; Sobczyk, Monika; Zheng, Jim; Lu, Bing; Mikaelian, Igor; Brockett, Robert; Jin, Debi; Wang, Ruth; Kanwar, Bittoo; Smith, Victoria
Journal:
Inflammatory bowel diseases
Issue:
Volume 23(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Oral Peptide Therapeutic PN‐10943 (alpha4beta7 Integrin Antagonist) in Normal Healthy Volunteers: 730. (October 2019)

Authors:
Gupta, Suneel K.; Cheng, Xiaoli; Kanwar, Bittoo; Matheakis, Larry; Bhandari, Ashok; Liu, David; Shames, Rich
Journal:
American journal of gastroenterology
Issue:
Volume 114 (2019)ACG Abstracts 1:Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Safety, Tolerability, and Pharmacokinetics of PTG‐200, an Oral GI‐Restricted Peptide Antagonist of IL‐23 Receptor, in Normal Healthy Volunteers: 751. (October 2019)

Authors:
Cheng, Xiaoli; Lee, Tien‐Yi; Ledet, Grace; Zemade, Genet; Tovera, James; Campbell, Robert; Purro, Nobert; Annamalai, Thamil; Masjedizadeh, Mohammad; Liu, David; Nawabi, Roya; Kanwar, Bittoo
Journal:
American journal of gastroenterology
Issue:
Volume 114 (2019)ACG Abstracts 1:Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial. (6th July 2016)

Authors:
Meissner, Eric G.; McLaughlin, Mary; Matthews, Lindsay; Gharib, Ahmed M.; Wood, Bradford J.; Levy, Elliot; Sinkus, Ralph; Virtaneva, Kimmo; Sturdevant, Dan; Martens, Craig; Porcella, Stephen F.; Goodman, Zachary D.; Kanwar, Bittoo; Myers, Robert P.; Subramanian, Mani; Hadigan, Colleen; Masur, Hen...
Journal:
Liver international
Issue:
Volume 36:Number 12(2016)
Page Start:
1783
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infection. Issue 4 (26th August 2017)

Authors:
Wirth, Stefan; Rosenthal, Philip; Gonzalez‐Peralta, Regino P.; Jonas, Maureen M.; Balistreri, William F.; Lin, Chuan‐Hao; Hardikar, Winita; Kersey, Kathryn; Massetto, Benedetta; Kanwar, Bittoo; Brainard, Diana M.; Shao, Jiang; Svarovskaia, Evguenia; Kirby, Brian; Arnon, Ronen; Murray, Karen F.; S...
Journal:
Hepatology
Issue:
Volume 66:Issue 4(2017)
Page Start:
1102
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed. Issue 1 (20th May 2015)

Authors:
Pol, Stanislas; Sulkowski, Mark S.; Hassanein, Tarek; Gane, Edward J.; Liu, Lin; Mo, Hongmei; Doehle, Brian; Kanwar, Bittoo; Brainard, Diana; Subramanian, G. Mani; Symonds, William T.; McHutchison, John G.; Nahass, Ronald G.; Bennett, Michael; Jacobson, Ira M.
Journal:
Hepatology
Issue:
Volume 62:Issue 1(2015:Jul.)
Page Start:
129
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗